CN111801323A - 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 - Google Patents
玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 Download PDFInfo
- Publication number
- CN111801323A CN111801323A CN201880090731.6A CN201880090731A CN111801323A CN 111801323 A CN111801323 A CN 111801323A CN 201880090731 A CN201880090731 A CN 201880090731A CN 111801323 A CN111801323 A CN 111801323A
- Authority
- CN
- China
- Prior art keywords
- degrees
- mesylate
- bemaciclib
- crystalline
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种玻玛西尼甲磺酸盐的晶型，其与已知的玻玛西尼甲磺酸盐相比具有一种或多种改进的特性。还涉及该玛西尼甲磺酸盐晶型的制备方法，药物组合物及其在制备用于治疗结肠直肠癌、乳腺癌、肺癌、前列腺癌、胶质母细胞瘤、套细胞淋巴瘤、慢性粒细胞白血病和急性粒细胞白血病等癌症疾病的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (26)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/083152 WO2019200502A1 (zh) | 2018-04-16 | 2018-04-16 | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111801323A true CN111801323A (zh) | 2020-10-20 |
Family
ID=68240525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880090731.6A Withdrawn CN111801323A (zh) | 2018-04-16 | 2018-04-16 | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20210179585A1 (zh) |
| CN (1) | CN111801323A (zh) |
| WO (1) | WO2019200502A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021030843A1 (en) | 2019-08-13 | 2021-02-18 | Johnson Matthey Public Limited Company | Solid-state forms of abemaciclib, their use and preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (en) * | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Protein kinase inhibitors |
| CN106008468A (zh) * | 2016-06-07 | 2016-10-12 | 上海宣创生物科技有限公司 | 玻玛西尼a晶型、b晶型、c晶型及其制备方法 |
| CN107868082A (zh) * | 2016-09-22 | 2018-04-03 | 上海宣创生物科技有限公司 | 玻玛西尼甲磺酸盐a晶型及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2014109858A1 (en) * | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| CN104529904B (zh) * | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
-
2018
- 2018-04-16 WO PCT/CN2018/083152 patent/WO2019200502A1/zh active Application Filing
- 2018-04-16 US US17/048,384 patent/US20210179585A1/en not_active Abandoned
- 2018-04-16 CN CN201880090731.6A patent/CN111801323A/zh not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075074A1 (en) * | 2008-12-22 | 2010-07-01 | Eli Lilly And Company | Protein kinase inhibitors |
| CN106008468A (zh) * | 2016-06-07 | 2016-10-12 | 上海宣创生物科技有限公司 | 玻玛西尼a晶型、b晶型、c晶型及其制备方法 |
| CN107868082A (zh) * | 2016-09-22 | 2018-04-03 | 上海宣创生物科技有限公司 | 玻玛西尼甲磺酸盐a晶型及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019200502A1 (zh) | 2019-10-24 |
| US20210179585A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2414470C2 (ru) | Кристаллические формы соединения тиазолидиндиона и способ его получения | |
| WO2022017533A1 (zh) | 用作cdk7激酶抑制剂的化合物及其应用 | |
| TWI447114B (zh) | 阿齊沙坦的新晶型及其製備方法 | |
| JP2007302658A (ja) | イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法 | |
| KR20120033357A (ko) | 다사티닙 다형체 및 이의 제조 방법 | |
| CN106661015B (zh) | 达沙替尼盐 | |
| EA021805B1 (ru) | Кристаллические соли эффективного ингибитора вируса гепатита с | |
| US11897858B2 (en) | Salt and solid state forms of escatalopram | |
| WO2017106641A1 (en) | Solid state forms of brexpiprazole | |
| CN110944979B (zh) | Odm-201晶型及其制备方法和药物组合物 | |
| CN110582497B (zh) | Galunisertib的晶型及其制备方法和药物组合物 | |
| US10071999B2 (en) | Crystalline forms of (3-amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine | |
| CN111801323A (zh) | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 | |
| CN110582279B (zh) | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 | |
| RU2712226C2 (ru) | Фениламинопиримидин или полиморфная форма соли фениламинопиримидина | |
| JP2021533111A (ja) | Ｌｔａ４ｈ阻害剤の結晶形態 | |
| WO2020156150A1 (zh) | 泊马度胺前体药物盐的多晶型物 | |
| WO2024056079A1 (zh) | 内匹司他酸加成盐的多晶型及其制备方法和用途 | |
| US20230373998A1 (en) | Solid state forms of lorecivivint | |
| WO2022143897A1 (zh) | A-失碳-5α雄甾烷化合物的多晶型物 | |
| CN108137578B (zh) | Abt-199加成盐及其晶型、其制备方法和药物组合物 | |
| WO2021037185A1 (zh) | 一种低杂质含量的酪氨酸激酶抑制剂 | |
| WO2022197884A1 (en) | Solid state forms of zandelisib and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201020 |